Acromegaly companies focus on the development of treatments for acromegaly, a rare hormonal disorder characterized by the excessive production of growth hormone. These companies contribute to endocrinology research by providing medications, such as somatostatin analogs, to regulate growth hormone levels and manage symptoms associated with acromegaly.
Novartis Launched their Signifor (pasireotide) in some countries for the treatment of acromegaly patients who haven't responded adequately to other therapies. Partnering with patient advocacy groups to raise awareness about acromegaly and support research efforts.
Ipsen Received FDA approval for Somatuline Autogel (lanreotide acetate) for the treatment of acromegaly in adults under 18 years old, offering a new option for pediatric patients. Investing in research on novel long-acting somatostatin analogs for potentially less frequent dosing and improved disease control.
Chiasma Pharma Entered into a licensing agreement with Pfizer for their Octreotide capsules, expanding access to this long-acting acromegaly treatment. Collaborating with research institutions on innovative drug delivery systems for somatostatin analogs for potentially improved patient compliance.
Strongbridge Biopharma Developed and commercialized their SOMAVERT (pegvisomant) injection, a growth hormone receptor antagonist for acromegaly patients not adequately controlled by somatostatin analogs. Partnering with healthcare providers to ensure optimal use of SOMAVERT in acromegaly treatment.
Amryt Pharma Acquired AnaBios, gaining access to their potential oral treatment for acromegaly, currently in Phase 2b clinical trials. Focused on expanding their portfolio of treatments for rare endocrine diseases, including acromegaly.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)